Derriford Hospital's surgery service rating upgraded
'Duty of candour'
A report published from the CQC inspection said services had improved and patients were kept safe and protected from avoidable harm.It said inspectors found people could access the service and were supported with interpreters.They also found staff spoke positively about leaders, who understood the challenges of their roles and supported them effectively to help provide the best care to people.Other findings included staff having the right skills and experience to meet people's needs, and working with the local community to deliver "joined-up care".
Inspectors also found staff "understood duty of candour and were open and honest with people when things went wrong".Areas that inspectors found still needed work included pharmacy support for the service, which it said varied compared to other areas of the hospital.The CQC added it was concerned with "privacy issues" surrounding the orthopaedic operating theatres as the doors enabled people to see patients being taken in for surgery.It noted the trust had looked to address this issue following feedback by installing manual push buttons to open and close the doors as required.
'Positive energy'
Catherine Campbell, CQC deputy director of operations in the south, said the trust should be pleased with the progress made in its surgery services."When we inspected Derriford Hospital's surgery services we found staff and leaders had been committed to using the findings from our last inspection to make improvements and this had resulted in positive changes being made across the board," Ms Campbell added.Jo Beer, the trust's chief operating officer, said staff at the hospital had been given a huge boost by the inspection's findings and patients were feeling the benefit of the improvements."We are super proud of this CQC report," Ms Beer said. "It's created a huge amount of positive energy across the organisation, in particular surgery."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
10 minutes ago
- The Guardian
‘Hi-tech' hearing aids are also available on the NHS
The closing paragraphs of Lucy Knight's article ('I'm carrying survivor's guilt': Raymond Antrobus on growing up deaf, 9 August) may have left readers with a misleading impression of the services and quality of hearing aids provided by the NHS. 'Hi-tech' hearing aids that connect to a smartphone are standard issue with the NHS. True, the very latest models of hearing aids may only be available privately (though, like smartphones, I suspect that the upgrades are often minimal). Like the private sector, the NHS provision of hearing aids is also regularly upgraded. The replacement hearing aids I got this January provide excellent sound, and are a conduit for all the radio and podcast listening I need. Not a bad VoakesBradford Have an opinion on anything you've read in the Guardian today? Please email us your letter and it will be considered for publication in our letters section.
Telegraph
10 minutes ago
- Telegraph
NHS to hand out more fat jabs after private clinics raise prices
The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private patients, The Telegraph can reveal. GPs are being braced for a surge in demand for the 'King Kong' of weight-loss jabs after Eli Lilly, the US pharmaceutical firm, said it would be more than doubling its prices from Sept 1. Health officials have written to family doctors about an expected increase in demand from patients who had been accessing the drug privately, but will now turn to the NHS. The Government is also looking to intervene in the dramatic price rise, it is understood, amid fears that hundreds of thousands of patients currently benefiting from losing weight on the jabs could be forced to stop taking them. Eli Lilly said it was increasing the cost of Mounjaro – also known as tirzepatide – in the UK to bring it in line with 'other developed nations'. In July, Donald Trump demanded that drug manufacturers lower their prices for American patients and stop other countries 'freeloading' off US firms. The US president previously complained that a friend had the 'fat drug' in London for a fraction of its US price despite being 'the same box made in the same plant by the same company'. Eli Lilly is increasing the wholesale price UK retailers will pay for a middle-sized 5mg dose from £92 to £180, and for the maximum dose, 15mg, from £122 to £330. These costs are likely to be passed on to private patients, of which there are almost one million taking Mounjaro, most of whom will now face the choice of paying the increased rates or stopping the drug. But the NHS has said it will continue prescriptions for patients who had been accessing the drugs privately if they meet certain criteria. The health service has a commercial deal in place to roll out the jab at a cheaper price. The cost of a prescription to patients is £9.90. A letter from NHS officials to GPs seen by The Telegraph said the NHS could continue treatment 'for people that have previously accessed tirzepatide through a private provider' if they meet eligibility criteria when assessed by a weight management service. Under current guidance, patients must have a body mass index of 40 or more 'in addition to four or more qualifying comorbidities', such as diabetes and high blood pressure, as part of a phased rollout. From next April, people with a BMI of 35 or more will also be able to get the jab on the NHS, with plans to eventually roll it out to more than three million. People accessing the anti-obesity injections privately are supposed to have a BMI of more than 30, but some people have been 'cheating the system' in order to access it, according to Wes Streeting, the Health Secretary. It is not known how many people will be eligible to move over to an NHS prescription from a private one. There were 32,000 patients waiting for an appointment at a weight management service in the community as of the end of June. While the majority of patients are being seen within 18 weeks, more than 2,000 have been waiting for more than a year. NHS officials also said GPs should tell patients asking for weight-loss jabs if they are not currently eligible. This includes those who may have started treatment with a BMI of more than 40 but is now less. 'We recognise this may be disappointing for people,' the update said, adding that doctors 'could provide reassurance to the person that stopping tirzepatide, that is being taken for its licensed weight loss indication, is not known to cause withdrawal symptoms, but that they should continue, where appropriate, a reduced-calorie diet and increased physical activity if they want to reduce the risk of weight regain'. It said anyone with questions about stopping the drugs should be directed back to their private provider. More people could also turn to the other weight-loss jab available in the UK, rival brand Wegovy, made by Danish firm Novo Nordisk. A spokesman for the company, which also makes Ozempic, said they had 'no plans of changing our offering in the UK'. 'Our focus is on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most,' they said. 'Our mission is to help create a healthier world by addressing some of the most pressing threats to public health – including obesity, diabetes and cardiovascular disease.' A Department of Health spokesman said: 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to so do in a safe and controlled way. 'Pricing in the private market is a matter for Eli Lilly and for private providers of weight loss and diabetes services. Eli Lilly are working with providers to maintain patient access. 'NHS commissioning of tirzepatide, based on clinical priority, is unaffected by the change in list price.'
BBC News
40 minutes ago
- BBC News
Birmingham nursing home downgraded to inadequate
A care home in Birmingham has been rated inadequate by inspectors after failing to meet expected safety standards. Fountain Nursing and Care Home, on Fountain Road, was placed into special measures following an inspection by the Care Quality Commission (CQC).Its rating was downgraded from good after the body found nine breaches of regulations, despite residents and family members "generally positive" about the found that one resident, known to be at risk of falls, had sustained a head injury after falling - but staff did not seek timely medical advice or report it properly. The home has been contacted by the BBC for comment. The care home, run by a company of the same name, provides personal and nursing care - with 26 people living there at the time of the inspection in May. Inspectors said they were "disappointed" that the quality of care had "deteriorated considerably" since the previous inspection in 2020. The breaches related to a raft of areas including person-centred care, dignity and respect, consent, risk management, nutrition and hydration, premises and equipment safety, staffing, and Lyndon, CQC deputy director of operations in Birmingham, said the quality of leadership at the home had declined. She said: "Our experience tells us when a service isn't well-led, they find it difficult to provide good care in the other areas we look at, which is what we found here."Staff and leaders didn't recognise or report safeguarding concerns to protect people from potential abuse or harm."We saw leaders also failed to provide sufficient guidance for staff to safely manage people's health conditions and risks. They didn't ensure staff were adequately trained and had the relevant skills and knowledge to provide safe found the manager of the service was approachable, listened to concerns and supported also said residents and their relatives knew how to give feedback and felt comfortable raising the report noted that leaders "didn't provide clear information and guidance for staff" on supporting people with known health also said staff did not manage residents' nutrition and hydration needs "effectively". Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
